CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jan. 10, 2007--POZEN Inc.
(NASDAQ: POZN), a pharmaceutical company focused primarily on products
for the treatment of migraine, acute and chronic pain and other
pain-related conditions, today announced the appointment of Gilda M.
Thomas as Senior Vice President and General Counsel. Ms. Thomas will
be responsible for all legal matters affecting the Company, its
products, intellectual property, and employees.
Dr. John R. Plachetka, POZEN's Chairman, President and CEO said,
"We believe Ms. Thomas will be a great asset to the POZEN team. Ms.
Thomas has over 20 years of legal experience in the pharmaceutical
industry. She brings a wealth of knowledge related to general business
and commercial transactions, including intellectual property licensing
and general corporate law."
Ms. Thomas was most recently employed at EMD Pharmaceuticals,
Inc., an affiliate of Merck KGaA, Darmstadt, Germany as Vice
President, General Counsel and Company Secretary. In this capacity,
Ms. Thomas was responsible for overseeing and directing all legal
matters for a fully-integrated start up pharmaceutical company. Prior
to joining EMD in 2001, Ms. Thomas spent 14 years with Burroughs
Wellcome Co., which merged into Glaxo Wellcome, Inc. While at Glaxo
Wellcome, Ms. Thomas was Associate General Counsel responsible for the
13 member corporate section of the legal department.
Ms. Thomas received a J.D. (cum laude) from Harvard Law School, an
M.S. from Simmons College and an A.B. from Wellesley College.
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. POZEN's
efforts are focused primarily on the development of pharmaceutical
products for the treatment of acute and chronic pain and other
pain-related conditions. POZEN has development and commercialization
alliances with GlaxoSmithKline for the proposed product candidate
Trexima(TM) combining sumatriptan, formulated with RT Technology(TM),
and naproxen sodium in a single tablet for the acute treatment of
migraine, which is currently under review by the United States Food
and Drug Administration, and with AstraZeneca for proprietary fixed
dose combinations of the proton pump inhibitor esomeprazole magnesium
with naproxen in a single tablet for conditions such as osteoarthritis
and rheumatoid arthritis in patients who are at risk for developing
NSAID-associated gastric ulcers. The company's common stock is traded
on The Nasdaq Stock Market under the symbol "POZN". For detailed
company information, including copies of this and other press
releases, see POZEN's website: www.pozen.com.
Statements included in this press release that are not historical
in nature are "forward-looking statements" within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are subject
to a number of risks and uncertainties, including, but not limited to,
our failure to successfully commercialize our product candidates;
costs and delays in the development and/or FDA approval of our product
candidates, including as a result of the need to conduct additional
studies, or the failure to obtain such approval of our product
candidates, including as a result of changes in regulatory standards
or the regulatory environment during the development period of any of
our product candidates; uncertainties in clinical trial results or the
timing of such trials, resulting in, among other things, an extension
in the period over which we recognize deferred revenue or our failure
to achieve milestones that would have provided us with revenue; our
inability to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements necessary
for the development, manufacture, commercialization, marketing, sales
and distribution of any products; competitive factors; our inability
to protect our patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property to operate our
business; our inability to operate our business without infringing the
patents and proprietary rights of others; general economic conditions;
the failure of any products to gain market acceptance; our inability
to obtain any additional required financing; technological changes;
government regulation; changes in industry practice; and one-time
events, including those discussed herein and in our Quarterly Report
on Form 10-Q for the period ended September 30, 2006. We do not intend
to update any of these factors or to publicly announce the results of
any revisions to these forward-looking statements.
CONTACT: POZEN Inc.
Chief Financial Officer
Director, Investor Relations
SOURCE: POZEN Inc.